Press Releases

21 December 2011 Success of the Simplified Cash Tender Offer for the Shares and bons de souscription d’actions of Novagali
Pharma SA by Santen Pharmaceutical Co., Ltd.  Download.pdf

14 November 2011 Novagali Pharma announces its revenue for the first nine months of 2011. Download.pdf

11 October 2011 Santen Pharmaceutical CO., LTD. completes the acquisition of a controlling interest in Novagali Pharma S.A. Download pdf

28 September 2011 Signing of an acquisition of a controlling interest in Novagali Pharma by Santen Pharmaceutical CO., LTD Download pdf

8 September 2011 Catioprost Phase II positive results Download pdf

31 August 2011 First-half results 2011 Download pdf

28 July 2011 Revenue for the first half of 2011 Download pdf

5 July 2011 Supervisory board strengthened significantly Download pdf

9 June 2011, exclusive distribution agreement for Nova23041 in the United States and Canada with Ardeo Download the pdf

12 May 2011, Revenue for the 1st quarter of 2011 Download the pdf

26 April 2011, 2010 Annual Results Download the pdf

14 April 2011, Novagali Pharma completes patients recruitment for it US Phase II clinical study with Catioprost® Download the pdf

5 April 2011, enrollment of the First Patients in a Pivotal Phase III Study of Cyclokat® for Dry Eye Disease Download the pdf

16 March 2011, appointment of Dr. Ronald R. Buggage as Chief Scientific Officer Download the pdf

February 28th 2011 revenue for the 4th quarter and full year ending December 31st 2010 Download the pdf

5 January 2011 Positive Scientific Advice received from the European Medicines Agency for the Phase III clinical trial of
Cyclokat® for the treatment of Dry Eye Disease Download the pdf